CI-980 in advanced melanoma and hormone refractory prostate cancer

CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory p...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 2000-05, Vol.18 (2), p.187-191
Main Authors: Ryan, C W, Shulman, K L, Richards, J M, Kugler, J W, Sosman, J A, Ansari, R H, Vokes, E E, Vogelzang, N J
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Binding sites
Cancer therapies
Carbamates - adverse effects
Carbamates - therapeutic use
Cell cycle
Chemotherapy
Disease
Drug dosages
Drug Resistance, Neoplasm
Female
Humans
Immunotherapy
Lung cancer
Male
Melanoma
Melanoma - drug therapy
Metastasis
Middle Aged
Neutropenia
Patients
Polymerization
Prostate cancer
Prostatic Neoplasms - drug therapy
Pyrazines - adverse effects
Pyrazines - therapeutic use
Pyridines - adverse effects
Pyridines - therapeutic use
Response rates
Skin cancer
Thrombocytopenia
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.
ISSN:0167-6997
1573-0646
DOI:10.1023/A:1006382014403